LUNDBECKFONDEN
Company
LUNDBECKFONDEN develops 3 assets, the furthest approved (bupropion in Depressive Disorder, Major). Mostly small molecule acting on SLC6A2, SLC6A3 and OPRM1.
- 3
- Assets
- Furthest
- Approved
- 14
- Trials
- 0
- Signals
Pipeline
3Inhibits norepinephrine and dopamine reuptake, increasing their availability in synapses.
Approved, Small molecule, SLC6A2, SLC6A3, Depressive Disorder, Major, seasonal affective disorder
Uncompetitive NMDA receptor antagonist protecting against glutamate excitotoxicity
Approved, Small molecule, GRIN2B, GRIN1, Alzheimer's disease, dementia
D1/D2 receptor dopamine agonist for advanced Parkinson's disease
Phase 2, Small molecule, DRD2, DRD1, Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
See ProSubsidiaries
13 assets, 14 trials
In the full profile
- Evidence behind the mechanisms7
- Trials26
- Similar companies6
Updated 10 Oct 2026 · 62 sources